BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...Phase III bladder cancer AstraZeneca plc (LSE:AZN; NYSE:AZN) said both arms of the Phase III DANUBE...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...LSE:AZN; NYSE:AZN) / Celgene Corp. (NASDAQ:CELG) Imfinzi durvalumab First-line treatment of urothelial carcinoma Ph III DANUBE...
BioCentury | May 19, 2017
Clinical News

AZ's Imfinzi gets accelerated approval in bladder cancer

...prices will vary based on health insurance status and individual prescriptions. The ongoing Phase III DANUBE...
BioCentury | May 1, 2017
Company News

AZ's Imfinzi gets accelerated approval in bladder cancer

...prices will vary based on health insurance status and individual prescriptions. The ongoing Phase III DANUBE...
BioCentury | Dec 12, 2016
Clinical News

Durvalumab regulatory update

...1108 to treat solid tumors. The company expects data in 2018 from the Phase III DANUBE...
BioCentury | Dec 10, 2016
Company News

Priority Review for durvalumab in bladder cancer

...1108 to treat solid tumors. The company expects data in 2018 from the Phase III DANUBE...
BioCentury | Oct 21, 2016
Top Story

Keytruda passes Phase III bladder cancer test

...May 18) . AstraZeneca plc (LSE:AZN; NYSE:AZN) expects data in 2018 from the Phase III DANUBE...
BioCentury | Feb 22, 2016
Clinical News

Durvalumab regulatory update

...trial. AZ is also evaluating the human IgG1 mAb targeting PD-L1 in the Phase III Danube...
BioCentury | Dec 22, 2008
Emerging Company Profile

Danube: Taking the pressure off glaucoma

...of aqueous humor. While both treatments slow disease progression, neither eliminates the eventual vision loss. Danube's...
...necrotic cell death," Katz said. In animal models, DNB-001 protected RGCs, which could prevent blindness. Danube...
...Danube's pipeline and provide it as a service to potential partners. Companies and Institutions Mentioned Danube Pharmaceuticals Inc....
BioCentury | Dec 22, 2008
Emerging Company Profile

Corporate Profile

Danube Pharmaceuticals Inc. New York, N.Y. Technology: Ion-channel modulator Disease focus: Ophthalmic Clinical status: Phase II Founded: 2006 by Peter Kash, Joshua Kazam and David Tanen University collaborators: Mount Sinai Medical School and University of...
Items per page:
1 - 10 of 17
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...Phase III bladder cancer AstraZeneca plc (LSE:AZN; NYSE:AZN) said both arms of the Phase III DANUBE...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...LSE:AZN; NYSE:AZN) / Celgene Corp. (NASDAQ:CELG) Imfinzi durvalumab First-line treatment of urothelial carcinoma Ph III DANUBE...
BioCentury | May 19, 2017
Clinical News

AZ's Imfinzi gets accelerated approval in bladder cancer

...prices will vary based on health insurance status and individual prescriptions. The ongoing Phase III DANUBE...
BioCentury | May 1, 2017
Company News

AZ's Imfinzi gets accelerated approval in bladder cancer

...prices will vary based on health insurance status and individual prescriptions. The ongoing Phase III DANUBE...
BioCentury | Dec 12, 2016
Clinical News

Durvalumab regulatory update

...1108 to treat solid tumors. The company expects data in 2018 from the Phase III DANUBE...
BioCentury | Dec 10, 2016
Company News

Priority Review for durvalumab in bladder cancer

...1108 to treat solid tumors. The company expects data in 2018 from the Phase III DANUBE...
BioCentury | Oct 21, 2016
Top Story

Keytruda passes Phase III bladder cancer test

...May 18) . AstraZeneca plc (LSE:AZN; NYSE:AZN) expects data in 2018 from the Phase III DANUBE...
BioCentury | Feb 22, 2016
Clinical News

Durvalumab regulatory update

...trial. AZ is also evaluating the human IgG1 mAb targeting PD-L1 in the Phase III Danube...
BioCentury | Dec 22, 2008
Emerging Company Profile

Danube: Taking the pressure off glaucoma

...of aqueous humor. While both treatments slow disease progression, neither eliminates the eventual vision loss. Danube's...
...necrotic cell death," Katz said. In animal models, DNB-001 protected RGCs, which could prevent blindness. Danube...
...Danube's pipeline and provide it as a service to potential partners. Companies and Institutions Mentioned Danube Pharmaceuticals Inc....
BioCentury | Dec 22, 2008
Emerging Company Profile

Corporate Profile

Danube Pharmaceuticals Inc. New York, N.Y. Technology: Ion-channel modulator Disease focus: Ophthalmic Clinical status: Phase II Founded: 2006 by Peter Kash, Joshua Kazam and David Tanen University collaborators: Mount Sinai Medical School and University of...
Items per page:
1 - 10 of 17